Clinical Trial Update: Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sintilimab, anlotinib hydrochloride, and platinum-containing chemotherapy in metastatic/recurrent non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non Small Cell Lung Cancer
• Non-small Cell Lung Cancer
• Non-small Cell Squamous Lung Cancer

Drugs mentioned

• Anlotinib hydrochloride (anlotinib)
• Platinum-containing chemotherapy
• Sintilimab (sintilimab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Metastatic NSCLC, Recurrent NSCLC | Phase 2 | Status: UNKNOWN